Compare Adaptive Biotechnologies Corp (ADPT) vs Direxion Daily FTSE China Bull 3x Shares (YINN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? Adaptive Biotechnologies Corp trades at $25.41 (market cap $4.04B), while Direxion Daily FTSE China Bull 3x Shares trades at $28.9. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, Direxion Daily FTSE China Bull 3x Shares nearer its low. Which is the better fit depends on your goals.
| ADPT | YINN | |
|---|---|---|
Market Cap | $4.04B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $25.45 | $56.62 |
52-Week Low | $12.30 | $21.45 |
Enterprise Value | $4.10B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adaptive Biotechnologies (ADPT) trades at $25.24, near its 52-week high, with a bullish technical outlook. The company is executing a strategic separation into a pure-play MRD diagnostics business, showing strong revenue growth of 49% year-over-year in MRD and improving margins. Despite persistent net losses, cash flow turned positive in 2025, and recent earnings have mostly beaten expectations, indicating operational progress.
The outlook is cautiously optimistic, driven by the business separation potentially unlocking value and the MRD segment's growth. Key risks include sustained profitability challenges and high valuation multiples. Analyst consensus is bullish with a $25.50 price target, but investors should weigh the growth potential against the company's current lack of earnings.
YINN, a leveraged ETF tracking Chinese stocks, trades at $29.01, down 10.19% amid broad bearish technical signals. Key support lies at $29, with RSI at 24.06 indicating potential oversold conditions. Recent news highlights China's AI investments and export strength, but U.S.-China tech tensions and regulatory scrutiny persist.
The outlook remains clouded by geopolitical risks and leveraged ETF decay, though oversold conditions may offer tactical opportunities. Risks include amplified volatility and policy shifts, requiring cautious positioning given the fund's structure and macro sensitivities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Direxion Daily FTSE China Bull 3x Shares
YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →
